Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.40 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23607113 | 0.83 | NPC1 (0.57) | HDAC2CHEK1HDAC1HDAC3IRAK4 | |
| SCHEMBL23607123 | 0.80 | PRKCA (0.48) | PIM1CHEK1PTPN11PRKCAPRKCQ | |
| SCHEMBL23607121 | 0.76 | ATR (0.51) | PIM1HDAC2HDAC1HDAC3KDM4E | |
| SCHEMBL25131885 | 0.75 | KDM4E (0.52) | PIM1HDAC2CHEK1PTPN11HDAC1 | |
| SCHEMBL23607127 | 0.72 | PIM1 (0.44) | PIM1PIM3EGLN2FTO | |
| SCHEMBL25132256 | 0.70 | PIM1 (0.49) | PIM1PIM3EGLN2FTO | |
| SCHEMBL14284386 | 0.69 | NPC1 (0.61) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL23607118 | 0.68 | PIM1 (0.49) | PIM1HDAC2CHEK1PTPN11HDAC1 | |
| SCHEMBL24107779 | 0.66 | CHRNB2 (0.50) | HDAC2CHEK1HDAC1HDAC3 | |
| SCHEMBL30292566 | 0.65 | PIM1 (0.41) | PIM1HDAC2CHEK1HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | PIM1 1216/4885HDAC2 250/4885CHEK1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.